Literature DB >> 17912039

p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma.

Lindi Chen1, Archie J Malcolm, Katrina M Wood, Michael Cole, Sadick Variend, Catherine Cullinane, Andrew D J Pearson, John Lunec, Deborah A Tweddle.   

Abstract

Aberrant cytoplasmic sequestration has been reported as an alternative mechanism of p53 inactivation to mutation in neuroblastoma. We hypothesized that p53 localization and function in neuroblastoma is related to differentiation status. Eighty-two untreated and 24 paired pre and post-chemotherapy neuroblastomas were studied by immunocytochemistry for p53, p21(WAF1), BAX, Bcl2 and Ki67. Predominantly nuclear p53 was detected in undifferentiated neuroblastoma, and both nuclear and cytoplasmic p53 in differentiating neuroblastoma. The nuclear p53 labeling index (LI) correlated with the Ki67 LI (r = 0.51, p <0.001), and weakly with p21(WAF1) (r = 0.37), but not with BAX or Bcl2. There was a significant reduction in p53, p21(WAF1) and Ki67 LI after chemotherapy (p < 0.01), an increase in BAX (p <0.05), but no change in Bcl2. p53 localization and function were examined in two p53 wild-type undifferentiated and 9-cis retinoic acid differentiated neuroblastoma cell lines. Using immunocytochemistry, immunofluorescence and cell fractionation, p53 was found to be predominantly nuclear in both undifferentiated and differentiated cells. Following irradiation, there was upregulation of p53, p21(WAF1) and MDM2, but less induced PARP and caspase 3 cleavage in differentiated cells, suggesting intact p53 transcriptional function, but resistance to apoptosis. p53 function in undifferentiated and differentiated cells was confirmed by upregulation of p21(WAF1) and MDM2 following Nutlin-3 treatment. In conclusion, p53 is predominantly nuclear and functional in neuroblastoma regardless of differentiation status.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912039     DOI: 10.4161/cc.6.21.4853

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  16 in total

Review 1.  Breaking the Fourth Wall: Modulating Quaternary Associations for Protein Regulation and Drug Discovery.

Authors:  Marcus J C Long; Dziyana Hnedzko; Bo Kyoung Kim; Yimon Aye
Journal:  Chembiochem       Date:  2019-04-01       Impact factor: 3.164

2.  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

Authors:  Jane Carr-Wilkinson; Kieran O'Toole; Katrina M Wood; Christine C Challen; Angela G Baker; Julian R Board; Laura Evans; Michael Cole; Nai-Kong V Cheung; Joachim Boos; Gabriele Köhler; Ivo Leuschner; Andrew D J Pearson; John Lunec; Deborah A Tweddle
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

3.  p53 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Lindi Chen; Nunzio Iraci; Samuele Gherardi; Laura D Gamble; Katrina M Wood; Giovanni Perini; John Lunec; Deborah A Tweddle
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

Review 4.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

5.  Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Authors:  Zaowen Chen; Yunfu Lin; Eveline Barbieri; Sue Burlingame; John Hicks; Andrew Ludwig; Jason M Shohet
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

6.  Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Authors:  Jan J Molenaar; Marli E Ebus; Dirk Geerts; Jan Koster; Fieke Lamers; Linda J Valentijn; Ellen M Westerhout; Rogier Versteeg; Huib N Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-12       Impact factor: 11.205

Review 7.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679

8.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

9.  Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.

Authors:  Veronica Veschi; Marialaura Petroni; Beatrice Cardinali; Carlo Dominici; Isabella Screpanti; Luigi Frati; Armando Bartolazzi; Alberto Gulino; Giuseppe Giannini
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

10.  Aluminium induced endoplasmic reticulum stress mediated cell death in SH-SY5Y neuroblastoma cell line is independent of p53.

Authors:  Syed Husain Mustafa Rizvi; Arshiya Parveen; Anoop K Verma; Iqbal Ahmad; Md Arshad; Abbas Ali Mahdi
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.